Edwards Lifesciences
1,093 hedge funds and large institutions have $40.3B invested in Edwards Lifesciences in 2019 Q4 according to their latest regulatory filings, with 197 funds opening new positions, 351 increasing their positions, 358 reducing their positions, and 54 closing their positions.
265% more first-time investments, than exits
New positions opened: 197 | Existing positions closed: 54
13% more funds holding
Funds holding: 965 → 1,093 (+128)
6% more capital invested
Capital invested by funds: $37.9B → $40.3B (+$2.39B)
0.07% less ownership
Funds ownership: 248.88% → 248.81% (-0.07%)
1% less call options, than puts
Call options by funds: $259M | Put options by funds: $261M
2% less repeat investments, than reductions
Existing positions increased: 351 | Existing positions reduced: 358
3% less funds holding in top 10
Funds holding in top 10: 30 → 29 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$386M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$160M |
| 3 |
Goldman Sachs
New York
|
+$143M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$128M |
| 5 |
Two Sigma Investments
New York
|
+$123M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$312M |
| 2 |
Jennison Associates
New York
|
-$286M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$223M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$201M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$118M |
EW Hedge Fund Activity: Q4 2019 in Review
1,093 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2019, worth a combined $40.3B — up 6.3% from $37.9B a quarter earlier.
Buyers outnumbered sellers: 197 funds opened new EW positions and 54 closed out — a net gain of 143 holders — while 351 added to existing stakes and 358 trimmed.
The largest buyer was BlackRock, adding an estimated $386M. The largest seller was Sands Capital Management, cutting an estimated $312M.
- 1,093 institutional investors held Edwards Lifesciences (EW) as of Q4 2019, up from 965 in Q3 2019.
- Funds reported $40.3B of Edwards Lifesciences stock for Q4 2019, up 6.3% quarter-over-quarter.
- 197 funds opened new Edwards Lifesciences positions in Q4 2019 and 54 closed out, a net change of +143 holders.
- The largest Edwards Lifesciences buyer in Q4 2019 was BlackRock, an estimated $386M added.
- The largest Edwards Lifesciences seller in Q4 2019 was Sands Capital Management, an estimated $312M sold.
Based on aggregated 13F filings for Q4 2019.